|
AstraZeneca to Pay $520 Million to Settle Drug Probe |
|
Thursday, 29 April 2010 |
|
April 27 (Bloomberg) -- AstraZeneca Plc agreed to pay $520 million to resolve U.S. allegations that it illegally marketed the schizophrenia drug Seroquel for uses that weren’t approved by regulators. |
|
Read more...
|
|
|
Chemicals group Cognis targeted by bidders |
|
Thursday, 29 April 2010 |
|
April 14 (Reuters) - U.S. specialty chemicals maker Lubrizol Corp (LZ.N) has joined a string of other bidders in talks to buy Cognis GmbH [COGNS.UL] with an offer that could value the German maker of additives for cosmetics and detergents at about $4.1 billion, the Financial Times reported. |
|
Read more...
|
|
|
Roche quarterly sales climb 6% on cancer-drug demand |
|
Thursday, 29 April 2010 |
|
LONDON (MarketWatch) -- Roche Holding on Thursday said its first-quarter revenue climbed a stronger-than-forecast 6%, driven by demand for cancer drugs. |
|
Read more...
|
|
|
Nalco Reports First Quarter 2010 Financial Results |
|
Thursday, 29 April 2010 |
|
NAPERVILLE, Ill., April 27, 2010 (GLOBE NEWSWIRE) -- Nalco, providing essential expertise for water, energy and air, generated solid first-quarter revenue and earnings growth. Revenues increased 10 percent nominally. All three segments contributed positively to 4 percent organic improvement and currency effects added most of the remaining growth.
|
|
Read more...
|
|
|
Novartis buys additional Alnylam shares |
|
Thursday, 29 April 2010 |
|
Alnylam Pharmaceuticals Inc., a Cambridge life sciences company focused on gene-silencing technology, said that Novartis, the Swiss drug giant, has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of a 2005 agreement between the two companies. |
|
Read more...
|
|
|
